Obese Adults study: VK2735 Drug
Official title A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
ClinicalTrials.gov ID: NCT07838740
What this study is testing
What is VK2735?
An investigational medicine being studied as a potential treatment for obesity in adults.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how safe and well the drug is taken, how it moves through the body, and how it affects the body in people who are obese but otherwise healthy.
- Who it's for
- Adults who are obese (BMI 30 or higher) and do not have other medical conditions.
- What's involved
- Participants will receive either VK2735 or a placebo in a double‑blind, randomized design, and will have blood tests and other safety checks during the study.
- Time commitment
- The study lasts a few weeks, with several clinic visits for dosing and monitoring.
- Phase 1: an early, usually small safety study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Must be capable of giving a signed informed consent form (ICF).
- Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening...
- BMI ≥ 30 kg/m2.
- Willing to comply with contraceptive requirements.
You likely can't join if
- Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing...
- Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.
- Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.
- History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological...
- Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).
- Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).
See the full eligibility criteria
- Must be capable of giving a signed informed consent form (ICF).
- Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of...
- BMI ≥ 30 kg/m2.
- Willing to comply with contraceptive requirements.
- Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.
- Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.
- Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.
- History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder...
- Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).
- Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).
- Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level \> 3.0 times the ULN for the reference range.
- Impaired renal function with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 as measured at Screening.
The study team makes the final eligibility decision.
Where it is enrolling
- Lake Forest, California, United States
- Miami, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Lake Forest, California, United States; Miami, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.